Human Data First
Biochemical and physiological differences between animals and humans pose significant challenges in translating preclinical safety and efficacy studies into clinical outcomes. While animal models continue to be an essential tool in biomedical research and drug discovery, the fact that nearly 90% of all animal-tested compounds fail in clinical trials underscores the need to adopt a more modern approach and add human data at the preclinical stage. Our advanced platform bridges the gap between preclinical testing and human-based clinical trials, saving company resources while potentially increasing the number of drugs that make it to market.
AnaBios’ advanced human tissue-based methods are enabling a modernized approach that integrates animal models with human ex vivo studies. This provides a very powerful strategy that combines the benefit of in vivo measurements (in animals) with the ability to generate human data (ex vivo) to overcome the challenges of cross-species translation.
TARGET IDENTIFICATION
AnaBios offers a unique opportunity to study gene expression, proteomic and metabolomic profiles in authentic human tissues from healthy or diseased donors, providing great value when searching for new molecular targets or validating pre-selected targets.
LEAD IDENTIFICATION
Healthy and diseased human tissue samples enable the discovery of compounds with the desired selectivity profile. The high quality of samples procured by AnaBios enables the generation of highly dependable data for assessing the potential efficacy-related effects of a drug candidate or its toxicity risks.
LEAD OPTIMIZATION
AnaBios’ proprietary technology maximizes safety and efficacy of lead compounds with authentic human targets. By utilizing human cells and tissues, drug properties are improved by maintaining focus on the human target while keeping the desired activity in humans and minimizing misleading information due to species differences.
CLINICAL CANDIDATE SELECTION
Regulatory requirements mandate the use of animal models for toxicology studies, which are expensive and time consuming. By strategically leveraging the power of AnaBios’ technology to identify the molecules with the highest potential for suitable efficacy and safety profile in humans, programs can focus on conducting GLP toxicological studies on a few high value compounds. In addition, the generation of human data at the preclinical stage offers the opportunity to make informed decisions with regards to dosing in clinical studies.
CLINICAL TRIALS
AnaBios’ proprietary technology supports mechanistic studies to de-convolute clinical stage toxicity signals. Elucidating the mechanism of action enables the generation of risk mitigation strategies and allows continued development of the drug. Utilization of human cells and tissues provides a superior approach for clinical stage de-risking.
RNA INTEGRITY NUMBERS (RIN)
The high quality of AnaBios procured human tissue is verified through the RNA Integrity Number (RIN) score. Higher RIN scores equate to higher quality human tissue with less RNA degradation (Schroeder et al., 2006) and preservation of critical activity-dependent genes that are more susceptible to postmortem RNA degradation (Dachet et al., 2021).
Our RIN scores are determined via the Agilent BioAnalyzer 2100 and Expert Analysis Software and mean values from healthy tissue (above) show 25% to 40% higher than those from other suppliers (in-house data compared to that of the GTEx Consortium). The Industry-leading RIN scores from AnaBios healthy and diseased human tissue samples ensure the highest quality human tissue for discovery programs.
High quality RNA that can be used for expression analysis is indicated by a RIN score greater than 7, which indicates that RNA remains intact and not degraded during tissue recovery. All RIN scores were consistently above 7 with mean scores above 9. Diseased tissue samples have similar high quality.
HAVE MORE QUESTIONS?
CONTACT US
To inquire about our high-quality tissue and cells, as well as our functional assays, please go to the ‘Contact Us’ page by clicking the button below.